Molecular confirmation of the relationship between Candida guilliermondii Fks1p naturally occurring amino acid substitutions and its intrinsic reduced echinocandin susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Dudiuk, Catiana ^a,b   MacEdo, Daiana ^a   Leonardelli, Florencia ^a,b   Theill, Laura ^a   Cabeza, Matias S ^a,b   Gamarra, Soledad ^a   Garcia Effron, Guillermo ^a,b  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Candida guilliermondii; Echinocandin resistance; FKS mutations; Molecular mechanism

Indexed keywords

ECHINOCANDIN; ANTIFUNGAL AGENT; FKS1 PROTEIN, S CEREVISIAE; GLUCOSYLTRANSFERASE; MEMBRANE PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CHIMERA; CONTROLLED STUDY; FKS1P GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS MUTANT; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 85018179123     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02644-16     Document Type: Article

References (22)

1. Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ. 2014. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on nonalbicans Candida species. Mycoses 57:79-89. https://doi.org/10.1111/ myc.12104.
2. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356: 2472-2482. https://doi.org/10.1056/NEJMoa066906.
3. Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, Reisman AL, Biswas P, Walsh TJ. 2011. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 11:261. https://doi.org/10.1186/1471-2334-11-261.
4. Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin-Hong P, Tobin E, Kett DH, Biswas P, Swanson R. 2014. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis 14:97. https:// doi.org/10.1186/1471-2334-14-97.
5. Perlin DS. 2015. Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612-S617. https://doi.org/10.1093/cid/civ791.
6. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150-156. https://doi.org/10.1128/JCM.01901-07.
7. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 48:52-56. https://doi.org/10.1128/JCM.01590-09.
8. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52: 2305-2312. https://doi.org/10.1128/AAC.00262-08.
9. Sambrook J, Fritsch EF, Maniatis T. 1998. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
10. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of yeast; approved guideline - 2nd ed. CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeast; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Johnson ME, Katiyar SK, Edlind TD. 2011. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother 55:3774-3781. https://doi.org/10.1128/AAC.01811-10.
14. Katiyar SK, Edlind TD. 2009. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother 53:1772-1778. https://doi.org/10.1128/AAC.00020-09.
15. Douglas CM, Foor F, Marrinan JA, Morin N, Nielsen JB, Dahl AM, Mazur P, Baginsky W, Li W, el-Sherbeini M. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A 91: 12907-12911. https://doi.org/10.1073/pnas.91.26.12907.
16. Edlind TD, Henry KW, Vermitsky JP, Edlind MP, Raj S, Katiyar SK. 2005. Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast. Curr Genet 48:117-125. https://doi.org/10.1007/s00294-005-0008-3.
17. Gietz RD, Schiestl RH, Willems AR, Woods RA. 1995. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11:355-360. https://doi.org/10.1002/yea.320110408.
18. Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O, Isla G, Davel G. 2011. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 43:176-185.
19. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH AllianceR) registry, 2004-2008. Diagn Microbiol Infect Dis 74:323-331. https://doi.org/10.1016/j.diagmicrobio.2012.10.003.
20. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, Gibbs DL, Newell VA. 2006. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44:3551-3556. https://doi.org/10.1128/ JCM.00865-06.
21. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. https://doi.org/10.1086/ 596757.
22. Kabbara N, Lacroix C, Peffault de Latour R, Socie G, Ghannoum M, Ribaud P. 2008. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 93:639-640. https://doi.org/10.3324/haematol.11149.